XML 46 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($)
$ in Millions
3 Months Ended 48 Months Ended
Mar. 31, 2017
Sep. 30, 2016
Dec. 31, 2016
Jan. 06, 2016
Apr. 10, 2014
Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value $ 26.0   $ 28.5      
CellSorter [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration milestone payments (3.1) $ (32.0)        
(Decrease) increase in fair value of contingent consideration included in SGA   $ (12.6)        
Business Combination, Contingent Consideration, Liability     3.1     $ 44.6
Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability 26.0     $ 23.3    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances $ 0.6          
GnuBIO [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability     10.0   $ 10.7  
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00%          
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value Inputs, Entity Credit Risk 11.00%          
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Fair Value Inputs, Entity Credit Risk 4.60%          
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00%          
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0          
Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability [1] 26.0   38.5      
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability 22.8   24.0      
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Business Combination, Contingent Consideration, Liability $ 3.2   $ 14.5      
[1] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
March 31, 2017
 
December 31, 2016
Other current liabilities
$
3.2

 
$
14.5

Other long-term liabilities
22.8

 
24.0

   Total
$
26.0

 
$
38.5